USP2 and hepatocellular carcinoma: Importantly, the knockdown of USP2-AS1 markedly improved the therapeutic efficacy of the tyrosine kinase inhibitor lenvatinib and inhibited tumor growth in an in vivo model, indicating that targeting USP2-AS1 may reverse therapeutic resistance in hepatocellular carcinoma cells by disrupting HIF1α signaling (Chen et al., 2022).